Balyasny Asset Management’s Genocea Biosciences, Inc. GNCA Stock Holding History

Balyasny Asset Management’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-17,261	Closed	-$145K	–	2343
2018 Q1	$145K	Sell	17,261 -10,075	-37%	-$83.7K	﹤0.01%	1799
2017 Q4	$254K	Buy	27,336 +13,788	+102%	+$139K	﹤0.01%	1809
2017 Q3	$158K	Buy	+13,548	New	+$514K	﹤0.01%	1735
2016 Q3	–	Sell	-1,349	Closed	-$44K	–	1397
2016 Q2	$44K	Buy	+1,349	New	+$49.4K	﹤0.01%	1120
2016 Q1	–	Sell	-1,388	Closed	-$58K	–	1643
2015 Q4	$58K	Buy	+1,388	New	+$66.1K	﹤0.01%	1185

Other funds holding GNCA

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management's GNCA Position: Q2 2018 in Review

Balyasny Asset Management sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2018, closing a stake of 17,261 shares — an estimated $145K sold.

Balyasny Asset Management first reported a position in GNCA in Q4 2015 and held it in 5 quarters. The position peaked at $254K in Q4 2017. 54 funds tracked by Wall St. Rank hold GNCA as of Q2 2018.

Balyasny Asset Management reported no remaining Genocea Biosciences, Inc. position as of Q2 2018 after selling out during the quarter.
Balyasny Asset Management sold 17,261 Genocea Biosciences, Inc. shares in Q2 2018, an estimated $145K.
Balyasny Asset Management first reported a position in Genocea Biosciences, Inc. in Q4 2015 and held it in 5 quarters.
Balyasny Asset Management's Genocea Biosciences, Inc. position peaked at $254K in Q4 2017.
54 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2018.

Based on Balyasny Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.